Jowiseungchungtang Inhibits Amyloid-β Aggregation and Amyloid-β-Mediated Pathology in 5XFAD Mice

International Journal of Molecular Sciences

Sujin Kim¹  Minho Moon¹  SeongGak Jeon¹  SooJung Shin¹  HongSeok Choi¹  Seong-kyung Lee¹  Yunkwon Nam¹  YounSeok Lee¹  Yu-on Jeong¹  YongHo Park¹  Jwa-Jin Kim²  Dabi Kim³  Jin-il Kim⁴ 

[1] Department of Biochemistry, College of Medicine, Konyang University, 158, Gwanjeodong-ro, Seo-gu, Daejeon 35365, Korea;Department of Biomedical Science, Jungwon University, Geosan, Chungbuk 28024, Korea;Department of Medical Science, School of Medicine, Chungnam National University, Daejeon 35015, Korea;Department of Nursing, College of Nursing, Jeju National University, Jeju-si 63243, Korea;

关键词: Alzheimer’s disease;    amyloid-β;    jowiseungchungtang;    5XFAD mice;    neurodegeneration;    neuroinflammation;    adult hippocampal neurogenesis;   

DOI  :  10.3390/ijms19124026

来源: DOAJ

【 摘 要 】

Alzheimer’s disease (AD) is a neurodegenerative disease, which is accompanied by memory loss and cognitive dysfunction. Although a number of trials to treat AD are in progress, there are no drugs available that inhibit the progression of AD. As the aggregation of amyloid-β (Aβ) peptides in the brain is considered to be the major pathology of AD, inhibition of Aβ aggregation could be an effective strategy for AD treatment. Jowiseungchungtang (JWS) is a traditional oriental herbal formulation that has been shown to improve cognitive function in patients or animal models with dementia. However, there are no reports examining the effects of JWS on Aβ aggregation. Thus, we investigated whether JWS could protect against both Aβ aggregates and Aβ-mediated pathology such as neuroinflammation, neurodegeneration, and impaired adult neurogenesis in 5 five familial Alzheimer’s disease mutations (5XFAD) mice, an animal model for AD. In an in vitro thioflavin T assay, JWS showed a remarkable anti-Aβ aggregation effect. Histochemical analysis indicated that JWS had inhibitory effects on Aβ aggregation, Aβ-induced pathologies, and improved adult hippocampal neurogenesis in vivo. Taken together, these results suggest the therapeutic possibility of JWS for AD targeting Aβ aggregation, Aβ-mediated neurodegeneration, and impaired adult hippocampal neurogenesis.

【 授权许可】

Unknown